Latest in AIMS Psilocybin Right-To-Try Effort

Latest in AIMS Psilocybin Right-To-Try EffortWe have taken an additional step recently in our effort to secure psilocybin therapeutic use for two of our cancer patients under State and Federal Right to Try (RTT) laws. On Monday 3/8/21, on behalf of AIMS Institute and Dr. Aggarwal, lawyers filed a petition for review in U.S. Ninth Circuit Court of Appeals of the DEA’s written decision last month to deny our request for RTT access to psilocybin from a duly licensed producer.

Below is the press release that went out and links to some news stories that have appeared.

We are looking for leading organizations committed to protecting the rights of seriously ill patients to have immediate access to safe use of psychedelic-assisted therapy to file ‘friend of the court’ amicus briefs in the case. Please get in touch if your organization or one you know of is interested in lending their voice of support to help our patients receive therapeutic access to the eligible investigational drug psilocybin under right to try. We have a great opportunity here to help advance this very needed therapeutic modality in contemporary hospice and palliative care. Patients treated by palliative care and mental health specialists in Canada have already been able to avail fungal psilocybin-assisted therapy legally under Canadian government exemptions for the past 7 months, and it has been very beneficial in palliation of existential and other distress by all reports.

Press Release: NATION’S FIRST LEGAL CHALLENGE TO ALLOW PSILOCYBIN THERAPY IN END-OF-LIFE CARE UNDER “RIGHT-TO-TRY” LAWS MOVES FORWARD
https://goteamtbg.com/dying-patients-need-access-to-psilocybin-for-anxiety-and-depression-relief/

Oregon Public Broadcasting: Physicians ask DEA to rethink ban on psilocybin
https://www.opb.org/article/2021/03/09/physicians-ask-dea-to-rethink-ban-on-psilocybin/

Marijuana Moment: DEA Sued By Doctor Who Wants Permission To Give Psilocybin Mushrooms To Patients
https://www.marijuanamoment.net/dea-sued-by-therapists-who-want-permission-to-give-psilocybin-mushrooms-to-patients/

Clinician, Patients Take the Fight for Psilocybin To Court
https://www.psychiatrictimes.com/view/clinician-patients-take-fight-psilocybin-to-court

Why Dying Patients Are Suing for Access to Magic Mushrooms
https://today.westlaw.com/Document/Icf70e0e081e411eb835ee9025e2233da/View/FullText.html?transitionType=Default&contextData=(sc.Default)&VR=3.0&RS=cblt1.0

Seattle Doctor, Lawyer Speak Out on Landmark DEA Psilocybin Lawsuit
truffle.report/seattle-doctor-lawyer-speak-out-on-landmark-dea-psilocybin-lawsuit/

Seattle Doctor, Lawyer Speak Out on Landmark DEA Psilocybin Lawsuit
truffle.report/seattle-doctor-lawyer-speak-out-on-landmark-dea-psilocybin-lawsuit/

Suing the DEA for Access to Psilocybin
https://www.mushroomrevival.com/blogs/podcast/suing-the-dea-for-access-to-psilocybin?fbclid=IwAR1QLWYCMjISeWOdoHQVqlb1PaI1iA8NvsSgh7rut71VqZDQpAjU089fUBstruffle.report/seattle-doctor-lawyer-speak-out-on-landmark-dea-psilocybin-lawsuit/

 

Leave a Reply

Latest Blog Posts

Proactive Breast Health: Self-Care and Self-Exam Tips for Breast Cancer Prevention

Proactive Breast Health: Self-Care and Self-Exam Tips for Breast Cancer Prevention

by Clinical Consulting Team This post was written by our guest author, Raushanah Najeeullah, ND. Breast cancer affects approximately one in eight women, making it one of the most common cancers worldwide. While genetic factors can influence breast cancer risk, lifestyle choices and early detection play an important role in prevention. Nutrient and hormone influences, and possibly estrogen metabolism, might be contributors to breast cancer development. Select use of testing and addressing results, could influence optimal breast health and may be associated with reducing breast cancer risk. The DUTCH Test (Dried Urine Test for Comprehensive Hormones) provides potential valuable insights ...

Read More
New Urine Test Reduces Unnecessary Biopsies in Prostate Cancer Detection

New Urine Test Reduces Unnecessary Biopsies in Prostate Cancer Detection

Author: Raushanah Najeeullah, ND A new urine test, MyProstateScore 2.0 (MPS2), offers better accuracy for detecting high-grade prostate cancer compared to current methods. In a recent study involving over 1,500 men, MPS2 reduced unnecessary biopsies by up to 51% while still identifying significant cancers with high sensitivity. This test improves on the PSA test by specifically targeting 17 genes linked to high grade aggressive prostate cancer, making it a promising non-invasive tool for reducing the risks and discomfort associated with prostate cancer screening. Source: Tosoian JJ, Zhang Y, Xiao L, et al. Development and Validation of an 18-Gene Urine Test ...

Read More
Brain cancer update

Brain cancer update

July 12, 2024 Leanna Standish IV CURCUMIN AIMS Institute’s integrative oncology team is investigating the therapeutic effects of intravenous curcumin in treating the most aggressive type of brain cancer, called glioblastoma.  Curcumin is the molecule present in turmeric root that has anticancer activity.  Curcumin has been shown in cell culture experiments to cause the programmed death of glioblastoma cells.  We use IV curcumin in order to provide sufficient levels of curcumin to the brain that will slow tumor growth.  Our brain cancer patients are enrolled in AIMS Institute’s IRB-approved study called the AIMS CANCER OUTCOMES STUDY.  Last year we presented ...

Read More
Call Us Text Us
Skip to content